Nøvogene

Assay for Transposase-Accessible Chromatin with High Throughput Sequencing (ATAC-seq)

ATAC-seq is a high-throughput sequencing method for analysis of genome-wide chromatin accessibility, which is important for global epigenetic control of gene expression. Sequencing adapters are inserted into open chromatin regions by hyperactive Tn5 transposase. After PCR amplification, a sequencing library is constructed. All the open chromatin regions can be obtained under a specific space-time condition, not only limited to the binding sites of a transcription factor, or a certain histone modified region.

The Novogene Advantages

 Extensive Experience Hundreds projects successfully completed in 2020.
Data Guarantee

Strict quality control management ensures high-quality data.

Comprehensive Analysis

Our team of experienced scientists offer reliable analysis solutions to meet your project needs.

Project Workflow



Specifications		
SAMPLE REQUIREMENTS	Sample type: Tissues, live cells, or frozen cells Cell number: $\ge 1 \times 10^5$ cells, an accurate cell number is key to success of the experiment Tissue weight: ≥ 2 g fresh animal tissue	
SEQUENCING STRATEGY	Library type: 100-500 bp insert cDNA library (depends on peak distribution) Sequencing platform: NovaSeq 6000 Sequencing strategy: Paired-End 150 bp Recommended data output: 15 Gb raw data per sample	
TURNAROUND TIME	21 working days for 20 or fewer samples from verification of sample quality without data analysis	

Analysis Pipeline

Motif Prediction



---> Only applicable for projects with comparable experimental groups.

Novogene Powered Publications

Year	Journal	Title
2019	<i>Cancer Research</i>	SET Domain–Containing Protein 4 Epigenetically Controls Breast Cancer Stem Cell Quiescence
2019	<i>Scientific Data</i>	Transcriptome and Chromatin Accessibility in Porcine Intestinal Epithelial Cells upon Zearalenone Exposure

For Research Use Only. Exclusive for Clients in North and South America.



Novogene Corporation Inc.

8801 Folsom Blvd #290, Sacramento, CA 95826



58-383 Mainquiry_us@novogene.com

om en.novogene.com

Copyright©2011-2021 Novogene Corporation.

Follow us on LinkedIn

All Rights Reserved. Information and specifications are subject to change at any time without notice.